Geoffrey Saunders

Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study

Saye Khoo, Richard J. Fitzgerald, Sean Ewings et al. · Journal of Antimicrobial Chemotherapy · 2021 · 118 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +13

Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial

Saye Khoo, Richard J. Fitzgerald, Geoffrey Saunders et al. · The Lancet Infectious Diseases · 2022 · 80 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +14

Evaluation of the Harmonic Scalpel for Laparoscopic Bilateral Ovariectomy in Standing Horses

Katja F. Düsterdieck, R. Scott Pleasant, Otto I. Lanz et al. · Veterinary Surgery · 2003 · 53 citations

Veterinary Medicine, Surgery, Veterinary Surgery +12

Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial

I’ah Donovan-Banfield, Rebekah Penrice-Randal, Hannah Goldswain et al. · Nature Communications · 2022 · 42 citations · Full text

Life Sciences, Infectious Diseases, Pharmacotherapy +17

An Open Label, Adaptive, Phase 1 Trial of High‐Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS‐CoV‐2

Lauren Walker, Richard J. Fitzgerald, Geoffrey Saunders et al. · Clinical Pharmacology & Therapeutics · 2021 · 29 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +16